Literature DB >> 12898306

Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.

Jun Iwamoto1, Tsuyoshi Takeda, Shoichi Ichimura, Kenjiro Matsu, Mitsuyoshi Uzawa.   

Abstract

The purpose of the present open-labeled, randomized, prospective study was to compare the effects of cyclical etidronate combined with alfacalcidol with those of cyclical etidronate alone on lumbar bone mineral density (BMD), bone resorption, and back pain in postmenopausal women with osteoporosis. Forty postmenopausal women with osteoporosis, 60-86 years of age, without any vertebral fractures in the lumbar spine, were randomly divided into two groups with 20 patients in each group. One group was treated with cyclical etidronate (oral etidronate 200 mg daily for 2 weeks every 3 months) and the other was given cyclical etidronate combined with alfacalcidol (cyclical etidronate plus alfacalcidol 1 Ig daily continuously). The BMD of the lumbar spine (L1-L4) measured by dual-energy X-ray absorptiometry, urinary crosslinked N-terminal telopeptides of type I collagen (NTX) measured by an enzyme-linked immunosorbent assay, and back pain evaluated by the face scale score were assessed at baseline, 6 months, and 12 months. There were no significant differences in baseline characteristics including age, body mass index, years since menopause, lumbar BMD, urinary NTX level, and face scale score between the two treatment groups. Both treatments significantly reduced the urinary NTX level and back pain. Cyclical etidronate combined with alfacalcidol significantly increased the lumbar BMD with a more significant reduction in the urinary NTX level than cyclical etidronate alone, but cyclical etidronate alone did not significantly increase the lumbar BMD. Alleviation of back pain was similar in the two groups. These results suggest that cyclical etidronate combined with alfacalcidol appears to be more useful than cyclical etidronate alone for increasing the lumbar BMD by more markedly suppressing bone resorption in postmenopausal women with osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12898306     DOI: 10.1007/s00776-003-0655-5

Source DB:  PubMed          Journal:  J Orthop Sci        ISSN: 0949-2658            Impact factor:   1.601


  12 in total

1.  Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).

Authors:  J D Ringe; P Farahmand; E Schacht; A Rozehnal
Journal:  Rheumatol Int       Date:  2007-03       Impact factor: 2.631

2.  Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis.

Authors:  J Iwamoto; K Makita; Y Sato; T Takeda; H Matsumoto
Journal:  Osteoporos Int       Date:  2010-11-23       Impact factor: 4.507

Review 3.  Vitamin D deficiency: subclinical and clinical consequences on musculoskeletal health.

Authors:  Muhammad Haroon; Oliver FitzGerald
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

Review 4.  Efficacy of oral etidronate for skeletal diseases in Japan.

Authors:  Jun Iwamoto; Tsuyoshi Takeda; Yoshihiro Sato
Journal:  Yonsei Med J       Date:  2005-06-30       Impact factor: 2.759

Review 5.  Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol.

Authors:  J D Ringe; E Schacht
Journal:  Rheumatol Int       Date:  2007-08-01       Impact factor: 2.631

6.  Bone mineral density is not associated with musculoskeletal pain in postmenopausal Korean women aged ≥50 years.

Authors:  Kyoung Min Lee; Chin Youb Chung; Soon-Sun Kwon; Tae Gyun Kim; In Hyeok Lee; Ki Jin Jung; Jin Woo Park; Sang Young Moon; Moon Seok Park
Journal:  Clin Rheumatol       Date:  2014-10-07       Impact factor: 2.980

Review 7.  Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Authors:  G A Wells; A Cranney; J Peterson; M Boucher; B Shea; V Robinson; D Coyle; P Tugwell
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

8.  Eleven years of experience with bisphosphonate plus alfacalcidol treatment in a man with osteogenesis imperfecta type I.

Authors:  Jun Iwamoto; Yoshihiro Sato; Mitsuyoshi Uzawa; Hideo Matsumoto
Journal:  Ther Clin Risk Manag       Date:  2012-12-28       Impact factor: 2.423

9.  Vitamin D Deficiency and Pain: Clinical Evidence of Low Levels of Vitamin D and Supplementation in Chronic Pain States.

Authors:  Elspeth E Shipton; Edward A Shipton
Journal:  Pain Ther       Date:  2015-04-29

Review 10.  Vitamin D and Pain: Vitamin D and Its Role in the Aetiology and Maintenance of Chronic Pain States and Associated Comorbidities.

Authors:  Edward A Shipton; Elspeth E Shipton
Journal:  Pain Res Treat       Date:  2015-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.